Navigation Links
Novavax Announces Repayment of $5 Million of Convertible Debt
Date:7/15/2009

ROCKVILLE, Md., July 15 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it has repaid the remaining $5.0 million balance of its convertible notes. These convertible notes carried a coupon rate of 4.75% payable semi-annually and had a maturity date of July 15, 2009. Under the terms of the convertible notes, at its option, Novavax could pay up to 50% of the notes in the company's common stock subject to the satisfying certain conditions. Novavax has elected to pay 50% of the principal plus accrued and unpaid interest in cash for a total payment of approximately $2.6 million and issued common stock for the remaining $2.6 million of the principal plus accrued and unpaid interest due by dividing that principal amount by $2.5163, resulting in 1,016,939 shares of common stock.

"The repayment of the final portion of these convertible notes removes a significant financial liability from the company and results in a further strengthening of the balance sheet. Elimination of this debt will allow Novavax to focus on the various opportunities ahead including continued development of our seasonal flu and H1N1 pandemic flu vaccines as well as the realization of our technology in Spain and India to create self reliant in-border influenza vaccine supply," stated Rahul Singhvi, President and Chief Executive Officer of Novavax, Inc.

About Novavax

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines, including H1N1 influenza, to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
2. Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain
3. Novavax Appoints Stanley Erck to Board of Directors
4. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
5. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
6. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
7. Novavax Reports First Quarter 2009 Financial Results
8. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
9. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
10. Novavax Announces Early Retirement of $17 Million of Convertible Debt
11. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... NY (PRWEB) May 17, 2013 ... Topical BioMedics, Inc., has been listed among nationally ... in an initiative conducted by "U.S. News" Health ... has earned the “No. 1 Pharmacists Recommended ... 17 other national OTC brands, and is the ...
(Date:5/17/2013)... is available in German . ... with the naked eye, you can see which branch a ... blur of branches through the telephoto lens for high-magnification images ... who are looking to study proteins, the active biomolecules of ... Institute for Molecular Systems Biology, and her colleagues have now ...
(Date:5/17/2013)... PHILADELPHIA , May 17, 2013 ... held by the most innovative thought leaders of ... Device & Manufacturing East conference and expo, from ...      (Photo: http://photos.prnewswire.com/prnh/20130517/613829 ) ... were designed to deliver industry professionals practical presentations ...
(Date:5/17/2013)... , May 17, 2013  Insero Health, Inc., ... needs in epilepsy and related neurological disorders, is today ... its lead compound INS001 in patients with drug-resistant epilepsy.  ... and Device Trials (AED) Xll meeting by Dr. ... and Chairman of Insero,s Scientific Advisory Board.  In this ...
Breaking Biology Technology:Pharmacists' Picks: Topical BioMedics' Topricin Listed on Top Recommended OTC Health Products 2Proteome atlas for the tuberculosis pathogen 2Proteome atlas for the tuberculosis pathogen 3MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2
... , KALAMAZOO, Mich., Nov. 3 Tolera Therapeutics, Inc., ... application with the United States Food and Drug Administration ... acute rejection of solid organ transplantation. TOL101 is ... and specifically target T cells, components of the immune ...
... , SOUTH SAN FRANCISCO, Calif., Nov. 3 Poniard Pharmaceuticals, ... oncology, today reported financial results for the third quarter ended ... "During the third quarter, we reached the 320th event target ... picoplatin for the treatment of small cell lung cancer. ...
... November 3 The new market research,report, ,Global ... 2014),published by MarketsandMarkets ( http://www.marketsandmarkets.com ) analyzes,the major ... identifies and analyzes,the main market drivers, restraints, and ... submarkets in different,geographic regions. , ...
Cached Biology Technology:Tolera Therapeutics Files IND Application for TOL101, Appoints O'Toole to Lead Clinical Operations 2Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 2Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 3Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 4Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 5Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 6Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 7MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014 2MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014 3
(Date:5/16/2013)... a conservationist working in Cameroon and the manager of ... been awarded the prestigious Whitley award. The Whitley ... "The Green Oscars" because it celebrates the extraordinary achievements ... developing countries. Abwe was selected for the award ... Cameroon,s Ebo Forest and its wildlife inhabitants., HRH The ...
(Date:5/16/2013)... The consultancy Frost & Sullivan ... Germany,s largest biometrics manufacturer, DERMALOG ... DERMALOG has been honored yesterday night by ... the category Global Biometrics and Border Control  Customer Value ... Border Control System . One of the decisive factors ...
(Date:5/15/2013)... In the largest clinical trial to date to examine ... carriers with diseases other than breast and ovarian cancer, ... against advanced pancreatic and prostate cancers. Results of the ... Medicine at the University of Pennsylvania and Sheba Medical ... the American Society of Clinical Oncology,s annual meeting in ...
Breaking Biology News(10 mins):Cameroon researcher wins prestigious 'Green Oscar' 2Cameroon researcher wins prestigious 'Green Oscar' 3Global Biometrics and Border Control Award for DERMALOG 2Global Biometrics and Border Control Award for DERMALOG 3Global Biometrics and Border Control Award for DERMALOG 4PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations 2
... A new DNA-based prenatal blood test that can strikingly ... a pregnancy with Down syndrome is ready to be introduced ... as 10 weeks of pregnancy to women who have been ... are the results of an international, multicenter study published online ...
... BROOKLYN, NY October 17, 2011 The Peggy ... Scientific Officer and Senior Vice President of Optimer Pharmaceuticals, ... Medicine at Tufts University, with an achievement award to ... pursuit of new treatments for Clostridium difficile ...
... discovered that a gene known as an androgen receptor (AR) ... opposite effects on these diseases. In prostate cancer, the AR ... breast cancer, the AR gene promotes cancer growth when the gene ... AR production ceases in women. What this means is that ...
Cached Biology News:Study shows that new DNA test to identify Down syndrome in pregnancy is ready for clinical use 2Study shows that new DNA test to identify Down syndrome in pregnancy is ready for clinical use 3Peggy Lillis Foundation honors Dr. Sherwood Gorbach for career combating C. diff infection 2Peggy Lillis Foundation honors Dr. Sherwood Gorbach for career combating C. diff infection 3Researchers discover that same gene has opposite effects in prostate, breast cancers 2
... Anti-YAP Polyclonal Antibody ... purified rabbit polyclonal antibody. Detects 70 ... in Western blotting and immunohistochemistry. ... proliferation Storage: ...
Rabbit polyclonal to QKI...
Mouse polyclonal antibody to QPRT - quinolinate phosphoribosyltransferase (nicotinate-nucleotide pyrophosphorylase (carboxylating))...
... without ammonium sulfate are compatible with thermostable ... Taq and AmpliThem™™ DNA polymerases. You can ... in one experiment by adding your own ... PreMixes supplied with the kit. This capability ...
Biology Products: